Independent Laboratory, located in Bristol County, Massachusetts, is a CAP and CLIA-certified, independently operated clinical laboratory serving a strategically critical national client base.
The lab specializes in toxicology, clinical chemistry, hematology, and molecular diagnostics, delivering high-complexity services to healthcare providers, employers, and public health agencies. Its strengths include rigorous compliance, favorable payer contracts, advanced instrumentation, and a strong reputation in specialized diagnostic services.
In light of sector consolidation and evolving regulations for 2025, the lab is an attractive acquisition for hospital systems, private equity, or regional competitors seeking to expand diagnostic capabilities and market presence.
Business Highlights
The laboratory stands out for its operational resilience and breadth of testing, featuring the following core advantages:
• Comprehensive CAP & CLIA Accreditation: The lab’s Certificate of Accreditation is effective through September 2026. The lab also maintains multi-state documentation, enabling seamless regional and national operation, and is accredited by the College of American Pathologists (CAP).
• Specialized Service Portfolio: The laboratory offers high-complexity, non waived diagnostic testing in toxicology, clinical chemistry, hematology, and molecular diagnostics. Its service portfolio aligns with high-growth market segments and evolving healthcare and employer needs.
• Diverse and Stable Client Base: The laboratory’s clientele includes regional healthcare provider groups, pain management clinics, addiction treatment programs, skilled nursing facilities, employers (particularly those operating under federally regulated drug and alcohol workplace testing requirements), and public health agencies. This diversity supports revenue stability and maximizes income across payer types.
• Operational Track Record and Compliance: The laboratory has been active since 2006, upholding an exemplary compliance record. Quality control and proficiency testing procedures meet or exceed CLIA and CAP standards, a critical assurance in the face of 2025’s tightened regulatory environment.
• Leadership and Management: Led by experienced scientific directors with PhD’s, the laboratory has a tenured staff well-versed in advanced methodologies and regulatory standards, enabling both operational continuity and technical advancement.
Facility & Equipment
The laboratory operates from a purpose-built, independent laboratory facility covering all the infrastructural requirements for advanced diagnostic services:
• Facility Type: Standalone independent clinical laboratory. Additional space available for potential expansion or integration of new testing lines.
• Accreditation and Licensure: Certified under CLIA (through September 2026), with state registrations spanning Massachusetts, Pennsylvania, Rhode Island, New Hampshire, and New York. Accredited by the College of American Pathologists, ensuring adherence to rigorous quality systems.
Recent upgrades to laboratory automation, connectivity, and advanced molecular testing instrumentation position at or above industry standards for efficiency, quality, and scalability.
• Staffing: The laboratory employs a mix of medical technologists, technical supervisors, quality assurance managers, and administrative support, meeting or exceeding College of American Pathologists’ (CAP Q-Probe) staffing benchmarks for technical and management FTEs per test.

Financials:
Purchase Price: $8,145,000 (Business only)
Cash Flow: $905,000
Gross Revenue: $12,327,516
Inventory $16,000 (included in sale price)
Assets: $4,500,000 ( Estimated, included in sale price)
Real Estate: $2,000,000 (available but incidental to the sale , subject to commercial appraisal)
Employees: 100
Founded: 1974